ResultsIQ

ResultsIQ › Latest results › Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited Q2 FY27 results press release summary

NSE: SYMBIOTEC · BSE: 544889

Results press release of 5 Nov 2026, summarised by AI from the filing.

₹53 crs of milestone-based revenue from Complex Injectables recognised in Q2FY27, lifting consolidated revenue 43% Y-o-Y.

Key takeaways

  1. Milestone revenue ₹53 crs of milestone-based revenue from Complex Injectables recognised in Q2FY27, lifting consolidated revenue 43% Y-o-Y.

Original filing on BSE

Symbiotec Pharmalab Limited Q2 FY27 results

As filed: Revenue ₹280 cr, EBITDA ₹91.5 cr, PAT ₹51.7 cr, EBITDA margin 32.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹280 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹211 cr, EBITDA ₹59.2 cr, PAT ₹47.0 cr, EBITDA margin 28.1%. Not scored. No result for the same quarter last year. Share price after the results: +4.5% in 30 days (Nifty 500: −4.5%).

Past price moves after results do not indicate future moves. Not a recommendation.

Symbiotec Pharmalab Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.